Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03954236 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
A Phase 2 study of Non-sclerotic Cutaneous Chronic Graft-versus-host Disease, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03954236 is a Phase 2 study of Non-sclerotic Cutaneous Chronic Graft-versus-host Disease that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03954236, a Phase 2 study of Non-sclerotic Cutaneous Chronic Graft-versus-host Disease, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
Conditions Studied
Interventions
- DRUG topical ruxolitinib 1.5% cream
- OTHER Topical vehicle/moisturizer cream
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2027-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03954236
The ClinicalTrials.gov registry entry for NCT03954236 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-sclerotic Cutaneous Chronic Graft-versus-host Disease appearing as the primary indexed condition, and to 2 interventions - of which topical ruxolitinib 1.5% cream is the first listed.
NCT03954236 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03954236 about?
NCT03954236 is a clinical study titled "Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease". The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
What is the current status of trial NCT03954236?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2019-05-14. Estimated completion is 2027-02-06.
What conditions does trial NCT03954236 study?
This clinical trial studies the following conditions: Non-sclerotic Cutaneous Chronic Graft-versus-host Disease.
What interventions are being tested in trial NCT03954236?
The interventions under investigation include: topical ruxolitinib 1.5% cream (DRUG), Topical vehicle/moisturizer cream (OTHER).
Who is sponsoring clinical trial NCT03954236?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03954236 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.